European Drug Development Consulting
0540.806.771 · rovalta.com · 26/09/2026
European Drug Development Consulting
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOEuropean Drug Development Consulting is a Private limited company incorporated in 2013. Its main activity is: Public relations and communication activities. Its registered office is in Amay.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0540.806.771
- Incorporation
- 15/10/2013
- Legal form
- Private limited company
- Registered office
- Rue du Tambour(Jeh) 4
4540 Amay · WallonieSee on map - Contributed capital
- 18 600,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 12 filingsTrend over 12 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 319,9 k € | +0.5% | 318,4 k € | +14.8% | 277,3 k € | +172% | 102 k € | +74.9% | 58,3 k € |
| EBITDA | 311,2 k € | -1.5% | 316 k € | +15.2% | 274,2 k € | +180% | 98 k € | +70.9% | 57,4 k € |
| Operating result | 303 k € | +1.8% | 297,7 k € | +19.3% | 249,6 k € | +245% | 72,2 k € | +55.9% | 46,3 k € |
| Net result | 223,7 k € | +2.2% | 219 k € | +22.5% | 178,7 k € | +234% | 53,6 k € | +61.7% | 33,1 k € |
| Balance sheet | |||||||||
| Equity | 30,1 k € | +47.0% | 20,5 k € | 0.0% | 20,5 k € | 0.0% | 20,5 k € | -39.5% | 33,8 k € |
| Total assets | 163 k € | -1.0% | 164,7 k € | -9.3% | 181,6 k € | +9.6% | 165,7 k € | +11.5% | 148,6 k € |
| Cash | 68,8 k € | -1.9% | 70,1 k € | -21.2% | 89 k € | +25.3% | 71 k € | -7.5% | 76,7 k € |
| Debts | 131,9 k € | -7.9% | 143,2 k € | -10.6% | 160,3 k € | +10.5% | 145,1 k € | +26.4% | 114,7 k € |
| Other | |||||||||
| Workforce | – | – | – | – | – | ||||
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20251 active · 1 ended
Active mandates
Ended mandates
Other companies at this address
Rue du Tambour(Jeh) 4 4540 Amay| Company | CBE no. |
|---|---|
CP Architecture● Active | 0765.875.871 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 16/07/2026 | 26/06/2025 | 11/07/2024 | 07/07/2023 | 20/06/2022 | 02/08/2021 |
| General meeting | 27/04/2026 | 06/06/2025 | 07/06/2024 | 02/06/2023 | 03/06/2022 | 04/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 12 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 27/04/2026 | 16/07/2026 | French | |
| Micro model | 31/12/2024 | 06/06/2025 | 26/06/2025 | French | |
| Micro model | 31/12/2023 | 07/06/2024 | 11/07/2024 | French | |
| Micro model | 31/12/2022 | 02/06/2023 | 07/07/2023 | French | |
| Micro model | 31/12/2021 | 03/06/2022 | 20/06/2022 | French | |
| Abridged model | 31/12/2020 | 04/06/2021 | 02/08/2021 | French | |
| Abridged model | 31/12/2019 | 30/06/2020 | 24/08/2020 | French | |
| Abridged model | 31/12/2018 | 07/06/2019 | 14/08/2019 | French | |
| Abridged model | 31/12/2017 | 01/06/2018 | 21/08/2018 | French | |
| Abridged model | 31/12/2016 | 02/06/2017 | 31/08/2017 | French | |
| Abridged model | 31/12/2015 | 03/06/2016 | 31/08/2016 | French | |
| Abridged model | 31/12/2014 | 05/06/2015 | 13/07/2015 | French |
Valuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 1 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025223,7 k €↑
- 2024Annual accounts 2024219 k €↑
- 2023Annual accounts 2023178,7 k €↑
- 2022Annual accounts 202253,6 k €↑
- 2022Name changeE.D.D.C
- 2021Annual accounts 202133,1 k €↑
- 2020Annual accounts 202031,6 k €↓
- 2019Annual accounts 201959,3 k €↑
- 2018Annual accounts 201847,2 k €↓
- 2017Annual accounts 201749,6 k €↓
- 2016Annual accounts 201662,5 k €↓
- 2015Annual accounts 201575,3 k €↓
- 2014Annual accounts 2014101,5 k €
- 2014Name changeEuropean Drug Development Consulting
- 15/10/2013IncorporationPrivate limited company